Xenon Pharmaceuticals Inc. XENE
41.46 USD -0.64 (-1.52%)
Nov 12, 2026, 2:25 PM EST
40.62 Day range 42.20
33.38 52-week range 72.66
- YTD
- -7.50%
- 1 year
- +4.49%
News
seekingalpha.com Xenon Pharmaceuticals Inc. (XENE) Q3 2026 Earnings Call Transcript Xenon Pharmaceuticals Inc. (XENE) Q3 2026 Earnings Call Transcript
marketbeat.com Xenon Pharmaceuticals Q3 Earnings Call Highlights Xenon Pharmaceuticals NASDAQ: XENE expects pivotal depression study results in December, earlier than previously projected, while preparing for a potential U.S. launch of its lead epilepsy drug and…
benzinga.com Xenon Pharmaceuticals Q3 2026 Earnings Call Transcript Xenon Pharmaceuticals (NASDAQ:XENE) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Xenon Pharmaceuticals Q3 EPS $(1.11) Beats $(1.13) Estimate Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(1.11) per share which beat the analyst consensus estimate of $(1.13) by 1.77 percent. This is a 3.48 percent increase over losses of…
globenewswire.com Xenon Reports Q3 2026 Financial Results and Provides Business Update New Drug Application for azetukalner in focal seizures submitted to U.S. Food & Drug Administration in September 2026 Expanding potential opportunity in epilepsy through ongoing Phase 3 X-TOLE3 and…
benzinga.com Xenon Pharmaceuticals Announces Its XEN1701 Surpasses Target Profile; Data Presented During International Association For The Study Of Pain 2026 World Congress On Pain Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for…
benzinga.com Full Transcript: Xenon Pharmaceuticals Q2 2026 Earnings Call Xenon Pharmaceuticals (NASDAQ:XENE) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is…
benzinga.com Alpha Buying: 4 Biotech Stocks Insiders Are Betting On I can sit through a biotech presentation and come away convinced that the company has discovered the answer to half the problems in modern medicine. The slides look terrific. The market opportunity…
benzinga.com Guggenheim Assumes Xenon Pharmaceuticals at Buy, Announces Price Target of $73 Guggenheim analyst Delma Caiati assumes Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy rating and announces Price Target of $73.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers IM Cannabis (NASDAQ:IMCC) stock increased by 246.0% to $6.02 during Friday's regular session. The market value of their outstanding shares is at $1.0 million. SkyAI (NASDAQ:SKYA) stock rose…
benzinga.com Dow Falls Over 200 Points; Xenon Pharmaceuticals Shares Plunge U.S. stocks fell Friday as weak industrial data weighed; Dow slid 0.45%, materials lagged, energy rose, and European shares declined.
benzinga.com Xenon Stock Reaction Is Overblown: Analyst Xenon Pharmaceuticals submits an FDA application for azetukalner for seizures while voluntarily pausing enrollment in depression trials.
benzinga.com RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $70 RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $81 to $70.
benzinga.com US Stocks Mixed; Industrial Production Unchanged In August U.S. stocks mixed Friday: Nasdaq and S&P 500 edged higher, Dow slipped. Oil rose; industrial production was flat, while GIPR and IMCC surged.
benzinga.com Wedbush Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $55 Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $71 to $55.
benzinga.com This Netflix Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday Analysts downgraded Magna, Franklin BSP, and more revising price targets for several.
benzinga.com Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday Analysts downgraded XENE, NFLX and MGA, while raising price targets for OCS, INSW, ABEO and STNG.
benzinga.com Wells Fargo Maintains Overweight on Xenon Pharmaceuticals, Lowers Price Target to $64 Wells Fargo analyst Benjamin Burnett maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and lowers the price target from $69 to $64.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers IM Cannabis (NASDAQ:IMCC) stock rose 108.5% to $3.63 during Friday's pre-market session. The market value of their outstanding shares is at $1.0 million. Alaunos Therapeutics (NASDAQ:TCRT)…
benzinga.com Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. futures rise, but Xenon plunges 27.6% after pausing psychiatry trial enrollment over neuropsychiatric adverse events; other stocks also fall
benzinga.com Deutsche Bank Downgrades Xenon Pharmaceuticals to Hold, Lowers Price Target to $46 Deutsche Bank analyst David Hoang downgrades Xenon Pharmaceuticals (NASDAQ:XENE) from Buy to Hold and lowers the price target from $90 to $46.- benzinga.com Market-Moving News for September 18th TCRT: 69% | Alaunos Therapeutics On Thursday Filed Patent Application "Identification Of Neoantigen-Reactive T Cell Receptors" MEDS: 24% | DataMeds AI Settles Litigation Related To Outstanding Debt…
- benzinga.com Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60 Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and lowers the price target from $78 to $60.
benzinga.com Baird Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $90 Baird analyst Brian Skorney maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $97 to $90.
benzinga.com Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket Alaunos rose 21.8% after adopting amended bylaws; Cheetah Net led gainers, while Xenon dropped 27.6% after pausing study enrollment.
benzinga.com Xenon Pharmaceuticals (XENE) Shares Fall 25% After Hours: Here's Why Xenon Pharmaceuticals shares fell 25% after hours after pausing new patient enrollment in ongoing psychiatry clinical studies.
benzinga.com Aethlon Medical, Oklo, CID HoldCo, Xenon Pharmaceuticals and Moderna: Why These 5 Stocks Are on Investors' Radars Today Major U.S. indices closed higher on Thursday, with the Dow Jones Industrial Average rising 0.61% to 51,778.04- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares moved upwards by 30.0% to $2.08 during Thursday's after-market session. The company's market cap stands at $3.2 million. cbdMD (AMEX:YCBD) stock…
- benzinga.com Xenon Pharmaceuticals Announces Voluntarily Initiated A Temporary Pause Of Enrollment Of New Patients In Ongoing Psychiatry Studies Following Neuropsychiatric Adverse Events; Patients Currently Enrolled In The Ongoing Studies Remain Active In addition, the Company announced today that it has implemented a voluntary pause on enrollment for new patients in its ongoing clinical studies in major depressive disorder (MDD) and bipolar…
benzinga.com Xenon Pharmaceuticals Says X-NOVA2 Enrollment Reaches ~80% Of Its Initial Target Of 450 Patients; Topline Data Readout Expected Q1 2027 X-NOVA2 enrollment has reached approximately 80% of its initial target of 450 patients, which is sufficiently powered to demonstrate a clinically meaningful change in the study’s primary endpoint of…- benzinga.com Xenon Pharmaceuticals Submits NDA For Azetukalner In Focal Seizures To FDA New Drug Application for azetukalner in focal seizures submitted to U.S. Food and Drug Administration; X-TOLE3 and X-ACKT continue to enroll focal seizure and PGTCS patients, respectivelyEnrollment…
- benzinga.com Xenon Pharmaceuticals To Present 6 Azetukalner Data Sets, Including Encore Oral Presentation Of Topline Phase 3 X-TOLE2 Results At European Epilepsy Congress, Taking Place September 5-9, 2026 Six presentations planned, including encore oral presentation of topline X-TOLE2 efficacy and safety results New poster will highlight the mechanistic characterization of azetukalner, including its…
- benzinga.com RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $81 RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $82 to $81.
- benzinga.com Xenon Pharmaceuticals Q2 EPS $(1.11) Beats $(1.15) Estimate Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(1.11) per share which beat the analyst consensus estimate of $(1.15) by 2.63 percent. This is a 3.74 percent decrease over losses of…
benzinga.com Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out Biohaven (BHVN) shares fall as BofA downgrades the stock to Underperform, citing a risky profile ahead of key epilepsy trial data.
benzinga.com JP Morgan Maintains Overweight on Xenon Pharmaceuticals, Raises Price Target to $82 JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and raises the price target from $80 to $82.- benzinga.com JP Morgan Maintains Overweight on Xenon Pharmaceuticals, Raises Price Target to $80 JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and raises the price target from $77 to $80.
- benzinga.com RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $82 RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and raises the price target from $80 to $82.
- benzinga.com Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $78 Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and lowers the price target from $80 to $78.
- benzinga.com Reported Sunday, Xenon Presents Phase 3 X-TOLE2 Data Showing Azetukalner Delivers 53.2% Reduction In Monthly Seizure Frequency Versus 10.4% For Placebo In Focal Onset Seizures At AAN 2026 Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time pointsX-TOLE2 data featured in the Late-breaking Science session show 53.2% reduction in…
- benzinga.com Xenon To Highlight Topline Phase 3 X-TOLE2 Study Results For Azetukalner In FOS, And Poster Presentation Of Long-Term 48-Month Azetukalner Data From X-TOLE Open Label Extension Study At 2026 AAN Annual Meeting Five abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-TOLE2 study results for azetukalner in focal onset seizuresPoster presentations also include…
- benzinga.com Wedbush Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $63 Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $64 to $63.
benzinga.com AutoZone To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Tuesday Analysts change outlook on top names: Truist cut KFY price target, Oppenheimer raised AZO target, B. Riley slashed YEXT target, Stifel cut MTN target, RBC raised KNTK target, Truist cut MAA target,…- benzinga.com Wells Fargo Maintains Overweight on Xenon Pharmaceuticals, Raises Price Target to $68 Wells Fargo analyst Benjamin Burnett maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and raises the price target from $49 to $68.
- benzinga.com Wedbush Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $64 Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and raises the price target from $47 to $64.
- benzinga.com Deutsche Bank Maintains Buy on Xenon Pharmaceuticals, Raises Price Target to $90 Deutsche Bank analyst David Hoang maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and raises the price target from $56 to $90.
- benzinga.com HC Wainwright & Co. Maintains Buy on Xenon Pharmaceuticals, Raises Price Target to $74 HC Wainwright & Co. analyst Douglas Tsao maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and raises the price target from $53 to $74.
- benzinga.com Xenon Pharmaceuticals Commences $500M Common Stock Offering Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for…
benzinga.com Crude Oil Rises Around 4%; Xenon Pharmaceuticals Shares Surge US stocks fell, Nasdaq down 1%, Dow down 1.71%, S&P 500 down 1.43%. Energy shares down 0.1%, consumer discretionary stocks down 2.8%. ZIM stock up after Q4 results. Autozi shares up 143%, Xenon…- benzinga.com Needham Maintains Buy on Xenon Pharmaceuticals, Raises Price Target to $80 Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and raises the price target from $58 to $80.